

Meet The Professor: Optimizing the Management of Hepatobiliary Cancers —  
Part 2 of a 2-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was reported from the Phase III HIMALAYA trial investigating the efficacy of durvalumab with or without tremelimumab versus sorafenib for unresectable liver cancer?
  - a. Median overall survival (OS) was not met with any regimen
  - b. Durvalumab with tremelimumab improved OS compared to sorafenib
  - c. Durvalumab with tremelimumab did not improve OS compared to sorafenib
  - d. Durvalumab alone improved OS compared to durvalumab with tremelimumab
2. Which of the following selective pan-FGFR inhibitors is being evaluated for patients with unresectable or metastatic intrahepatic cholangiocarcinoma and an FGFR2 fusion in the Phase II FOENIX-CCA2 study?
  - a. Erdafitinib
  - b. Pemigatinib
  - c. Infigratinib
  - d. Futibatinib
3. The Phase III ClarIDHy trial demonstrated which of the following outcomes for patients with advanced cholangiocarcinoma and an IDH1 mutation?
  - a. A statistically significant improvement in progression-free survival (PFS) with ivosidenib compared to placebo
  - b. A statistically significant improvement in PFS with enasidenib compared to placebo
  - c. A statistically nonsignificant improvement in PFS with ivosidenib compared to placebo
  - d. A statistically nonsignificant improvement in PFS with enasidenib compared to placebo
4. Which of the following best describes the specific mechanism of action of the novel agent zanidatamab for HER2-expressing biliary tract cancers?
  - a. Binds to the ECD2 domain of HER2
  - b. Binds to the ECD4 domain of HER2
  - c. Binds to ECD2 and ECD4 on HER2
  - d. Binds to HER2 and HER3
5. The Phase II HERB trial demonstrated promising clinical activity with which of the following agents for HER2-positive or HER2-low biliary tract cancer?
  - a. Zanidatamab
  - b. Trastuzumab deruxtecan
  - c. Datopotamab deruxtecan
  - d. Trastuzumab with pertuzumab